The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Desouza Errol B since 2007.
The trader's CIK number is 1213895.
At the time of the last reporting, Desouza Errol B was the Officer of Albireo Pharma, Inc.. (stock ticker symbol ALBO).
Also see all insider trading activities at Albireo Pharma, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2015 | BIOD | 0 | $0 | 0 | $0 | 131,128 | $0 |
2014 | BIOD | 0 | $0 | 0 | $0 | 5,625 | $0 |
2012 | BIOD | 10,000 | $33,400 | 0 | $0 | 5,625 | $0 |
2012 | BIOD | 0 | $0 | 0 | $0 | 157,500 | $0 |
2011 | BIOD | 0 | $0 | 0 | $0 | 22,097 | $7,474 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2007 | TRGT | 0 | $0 | 0 | $0 | 4,333 | $324 |
1. Albireo Pharma, Inc. (BIOD)
2. Catalyst Biosciences, Inc. (TRGT)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2015-09-30 | BIOD | Option Ex | 131,128 | .00 | 0 |
2014-03-12 | BIOD | Option Ex | 5,625 | .00 | 0 |
2012-09-20 | BIOD | Buy | 10,000 | 3.34 | 33,400 |
2013-03-12 | BIOD | Option Ex | 5,625 | .00 | 0 |
2012-09-30 | BIOD | Option Ex | 56,250 | .00 | 0 |
2012-09-30 | BIOD | Option Ex | 56,250 | .00 | 0 |
2012-03-12 | BIOD | Option Ex | 45,000 | .00 | 0 |
2011-11-09 | BIOD | Option Ex | 12,254 | .61 | 7,474 |
2011-09-30 | BIOD | Option Ex | 9,843 | .00 | 0 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2007-08-31 | TRGT | Option Ex | 3,333 | .07 | 249 |
2007-02-01 | TRGT | Option Ex | 1,000 | .07 | 75 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Desouza Errol B (Officer of Albireo Pharma, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.